SCHEMBL23909509

SCHEMBL23909509

CC(n1cnc2cnc3ccccc3c21)C1(O)CC=CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.40
TSHR P16473 1/20 0.38
USP7 Q93009 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
USP19 O94966 2/20 0.31
ATM Q13315 1/20 0.31
POLB P06746 2/20 0.30
LMNA P02545 1/20 0.30
HRH2 P25021 1/20 0.30
ADRA1D P25100 1/20 0.30
HTR2A P28223 1/20 0.30
ADORA2A P29274 1/20 0.30
ADRA1A P35348 1/20 0.30
NUDT1 P36639 1/20 0.30
HTR2B P41595 1/20 0.30
PDE4D Q08499 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23909507 1.00 USP5 (0.40) USP5TSHRUSP7KMT2AMEN1
SCHEMBL29789959 1.00 USP5 (0.40) USP5TSHRUSP7KMT2AMEN1
SCHEMBL23909465 0.88 USP5 (0.40) USP5TSHRUSP7KMT2AMEN1
SCHEMBL23909466 0.88 USP5 (0.40) USP5TSHRUSP7KMT2AMEN1
SCHEMBL23909506 0.88 USP5 (0.40) USP5TSHRUSP7KMT2AMEN1
SCHEMBL23909503 0.84 USP5 (0.36) USP5TSHRUSP7KMT2AUSP19
SCHEMBL23909504 0.84 USP5 (0.36) USP5TSHRUSP7KMT2AUSP19
SCHEMBL23200467 0.79 TLR7 (0.53) USP5POLBLMNAHRH2ADRA1D
SCHEMBL23200468 0.79 TLR7 (0.53) USP5POLBLMNAHRH2ADRA1D
SCHEMBL9379418 0.75 USP5 (0.45) USP5TSHRKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-08-26 US disclosed
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-05-02 US disclosed
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-01-30 US disclosed
CN-112218864-B N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 3M创新有限公司 2023-09-08 CN disclosed
EP-3802536-B1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2022-07-13 EP disclosed
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 USP5 3028/4885TSHR 2738/4885USP7 3072/4885
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 USP5 3028/4885TSHR 2738/4885USP7 3072/4885
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 USP5 3372/4885TSHR 2631/4885USP7 3432/4885
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 USP5 3372/4885TSHR 2631/4885USP7 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.